Elanco Animal Health, a spin-off of Eli Lilly's global animal health medicines and vaccines business, raised $1.5 billion by offering 62.9 million shares at $24, above the range of $20 to $23. Elanco Animal Health plans to list on the NYSE under the symbol ELAN. Goldman Sachs, J.P. Morgan, Morgan Stanley, Barclays, BNP Paribas, Citi, Credit Suisse, Deutsche Bank, Evercore ISI and Cowen acted as lead managers on the deal.
